Full-Time

National Account Director

Commercial Payers

Updated on 8/1/2026

Intellia Therapeutics

Intellia Therapeutics

501-1,000 employees

CRISPR-Cas9 genome-editing therapeutics developer

Compensation Overview

$243k - $297k/yr

+ Annual cash bonus + New hire equity grant + Annual equity awards

Cambridge, MA, USA

In Person

Field-based role with travel up to 50%.

Category
Business & Strategy (1)
Required Skills
Data Analysis

Get referred to Intellia Therapeutics

See people who can refer or advise you

Requirements
  • A Bachelor's degree is required.
  • At least 8 years of pharmaceutical or biotechnology market access experience, payer account management, or managed markets strategy is required.
  • Candidates must have a proven track record of managing national commercial payer accounts, including pre-launch and launch readiness for specialty or rare disease products.
  • Candidates must have experience with innovative reimbursement models, especially value-based or indication-based contracting.
  • Candidates must understand payer decision-making processes, formulary management, medical policy development, and specialty pharmacy dynamics.
  • Candidates must be able to thrive in early-stage or launch environments while operating with agility and strategic foresight.
  • Candidates must be able to communicate complex scientific and economic data to non-scientific audiences.
  • Candidates must have project management and cross-functional leadership skills.
  • Candidates must have negotiation skills and analytical capabilities.
  • Candidates must be comfortable operating in ambiguity with a bias for action and accountability.
  • The role requires travel of up to 50%, including partner meetings, conferences, and internal cross-functional workshops.
Responsibilities
  • Lead strategic engagement with national and large regional commercial payers.
  • Build and manage relationships with key decision-makers across payer organizations.
  • Analyze the competitive landscape and coverage policies to anticipate payer needs and barriers.
  • Develop and execute early account engagement plans in anticipation of launch, educating payer stakeholders on gene editing science, disease burden, and the anticipated value proposition.
  • Partner with Market Access Strategy, Contracts and Pricing, Health Economics and Outcomes Research, Medical Affairs, Clinical, and Regulatory teams to develop and tailor payer-facing materials, including early scientific exchange, evidence dossiers, promotional information exchange presentations, and budget impact models.
  • Drive payer insight generation to inform pricing strategy, contracting models, and patient access programs in pre-launch and launch phases.
  • Collaborate with the internal launch team to support pull-through planning, distribution strategy, and affordability and access solutions.
  • Identify, shape, and lead negotiation of value-based or outcomes-based contracting opportunities when required.
  • Monitor and influence payer policy development relevant to gene editing and high-cost cell and gene therapies.
  • Serve as the internal voice of the payer and provide strategic guidance to senior leadership on coverage risks, opportunities, and commercial landscape dynamics.
  • Ensure all engagements and materials comply with legal, regulatory, and corporate standards.
  • Serve as a commercial liaison across Market Access Leadership, Medical Affairs, Marketing, Patient Services, Finance, and Regulatory to align strategic initiatives and execution plans supporting national account objectives.
  • Partner with Field Market Access, Trade, and Channel teams to co-develop and deliver integrated account strategies that enhance access, affordability, and distribution of gene therapy products across national payers, pharmacy benefit managers, integrated delivery networks, and specialty pharmacies.
  • Lead cross-functional account planning sessions to synthesize market insights, anticipate customer needs, and develop tailored engagement models that support therapeutic adoption and long-term value creation.
  • Collaborate with Clinical and Health Economics and Outcomes Research teams to translate complex scientific and economic value propositions into narratives for payer stakeholders.
  • Facilitate internal coordination and communication to deliver compliant, consistent messaging and solutions reflecting the organization's scientific innovation and commercial strategy.
  • Drive organizational readiness and pull-through efforts across functional teams before and after launch to support market access success.
Desired Qualifications
  • An MBA or other graduate degree is preferred.
Intellia Therapeutics

Intellia Therapeutics

View

Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Get referred to Intellia Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase 3 HAE results created a near-term FDA approval catalyst.
  • ATTR and HAE programs address high-unmet-need markets with clear clinical endpoints.
  • A broad CRISPR platform supports pipeline expansion beyond the lead programs.

What critics are saying

  • A late-stage regulatory setback would leave Intellia without approved revenue-generating products.
  • Systemic CRISPR safety or delivery failures would undermine the entire platform thesis.
  • Heavy competition from other gene-editing companies can compress valuation and financing terms.

What makes Intellia Therapeutics unique

  • Intellia leads systemic in vivo CRISPR editing with proprietary lipid nanoparticle delivery.
  • Its HAE and ATTR programs target severe rare diseases with single-dose intent.
  • The company combines in vivo and ex vivo programs across multiple therapeutic areas.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Family Planning Benefits

Fertility Treatment Support

Parenting Leave

Adoption Assistance

Childcare Support

Elder Care Support

Commuter Benefits

Meal Benefits

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-4%

2 year growth

-3%
Minaris Advanced Therapies
Apr 29th, 2026
Improving manufacturing reliability in cell and gene therapy: practical operational strategies.

Improving manufacturing reliability in cell and gene therapy: practical operational strategies. April 29, 2026 CDMO Services Cell Therapy Gene Therapy Viral Vectors Gain practical insight into how to improve manufacturing reliability, reduce cost per batch, and strengthen performance in cell and gene therapy programs. This webinar will demonstrate how structured assessment of materials, process steps, testing workflows, and operational handoffs reveals actionable opportunities to shorten timelines and reduce variability. Using real-world examples and techniques that can be applied across multiple therapy types and development stages, the session will show how early operational assessment and targeted workflow adjustments lead to measurable improvements. These include smoother transitions into GMP manufacturing, fewer late-stage process changes, and sustained success during routine production. Key takeaways * Learn how mapping the current state of a manufacturing program across materials, unit operations, testing, and handoffs reveals actionable opportunities to reduce cost, minimize variability, and improve right-first-time statistics * Understand how standardized workflows combined with expertise support smoother transitions into GMP manufacturing and reduce late-stage process changes * Review generalized case examples demonstrating reductions in cost per batch, improved manufacturing reliability, and sustained success during routine production * Gain a practical framework for evaluating your own program, identifying improvement priorities early, and working with partners to optimize processes without disrupting timelines About the speaker. Francesca Vitelli Vice President, Global Head of Process, Analytical Development and Innovation Francesca Vitelli, PhD, is a biotechnology leader with more than 20 years of experience in process and analytical development, manufacturing, and CMC strategy across cell and gene therapies. At Minaris Advanced Therapies, she leads global teams responsible for advancing innovative, platform-based manufacturing solutions for cell therapies and viral vectors, with a focus on de-risking CMC execution, enabling reliable GMP delivery, and accelerating the adoption of new technologies to improve scalability, robustness, and patient access. Previously, Dr. Vitelli served as Vice President at Intellia Therapeutics, where she led process development and manufacturing for both in vivo and ex vivo gene editing programs, expanding technical capabilities while driving operational efficiencies. Prior to Intellia, she held senior leadership roles at Lonza, where she launched large-scale viral vector manufacturing platforms and led cell therapy manufacturing for clinical and commercial-ready programs. Dr. Vitelli is recognized for her technical rigor, innovation-driven mindset, and ability to scale organizations through periods of rapid growth. She holds a PhD from the University of Siena. Related resources.

Yahoo Finance
Feb 28th, 2026
Intellia Therapeutics reports $605M cash reserves, expects runway into 2027

Intellia Therapeutics has reported its fiscal Q4 and full year 2025 financial results, with cash, cash equivalents and marketable securities of $605.1 million as of 31 December 2025, down from $861.7 million in the prior year. The company expects these funds to support operations into the second half of 2027, including through the anticipated US commercial launch of lonvo-z for hereditary angioedema. Collaboration revenue for Q4 reached $23.0 million, up from $12.9 million year-on-year, driven by $9.0 million from the termination of its licence agreement with SparingVision and increased cost reimbursements from its Regeneron collaboration. Research and development expenses fell to $88.7 million from $116.9 million in the prior year period. The clinical-stage company develops genome editing therapeutics using CRISPR/Cas9 technology.

Yahoo Finance
Feb 28th, 2026
Intellia completes phase 3 enrollment for lonvo-z, aims for mid-2026 data with $605M cash

Intellia Therapeutics has completed enrolment in its phase 3 HAELO trial for lonvo-z, expecting top-line data by mid-2026 and planning a biologics licence application submission in the second half of 2026. The company is preparing for a potential one-time hereditary angioedema treatment launch. The FDA placed Intellia's in vivo ATTR programme (nex-z) on clinical hold following liver enzyme events. The hold was lifted for the MAGNITUDE-2 polyneuropathy study with enhanced monitoring requirements, whilst the cardiomyopathy study remains on hold pending review. Intellia reported $605.1 million in cash as of 31 December 2025, sufficient to fund operations into the second half of 2027. The company posted a reduced fourth-quarter net loss of $95.8 million alongside higher collaboration revenue.

The Associated Press
Feb 26th, 2026
Intellia's lonvo-z for HAE targets mid-2026 Phase 3 data, BLA filing and 2027 US launch

Intellia Therapeutics reported fourth-quarter 2025 financial results and provided updates on its CRISPR gene-editing programmes. The company ended 2025 with approximately $605 million in cash, expected to fund operations into the second half of 2027. For lonvoguran ziclumeran (lonvo-z) treating hereditary angioedema, Intellia expects Phase 3 HAELO clinical data by mid-2026, with a biologics licence application submission in the second half of 2026 and anticipated US launch in the first half of 2027. The company completed dosing of 80 patients in September 2025. For nexiguran ziclumeran (nex-z) treating ATTR amyloidosis, Intellia is reactivating global sites for the MAGNITUDE-2 Phase 3 trial following the FDA's January 2026 clinical hold lift, with enrollment completion expected in the second half of 2026. Engagement continues regarding the clinical hold on the MAGNITUDE trial.

Yahoo Finance
Jan 20th, 2026
Intellia Therapeutics shares surge 35% in a month but trade 95% below DCF valuation

Intellia Therapeutics shares have surged 35.4% over the past month and 35.7% year-to-date, trading around $12.50. However, the stock scores just 2 out of 6 on valuation checks, suggesting the market prices it favourably on only a couple of basic tests. A discounted cash flow analysis estimates the company's intrinsic value at $233.98 per share, implying the stock is 94.7% undervalued at current levels. The model projects Intellia moving from negative free cash flow of $420 million in the latest twelve months to positive cash flow of approximately $370 million by 2030. Despite recent gains, the stock has posted weak longer-term returns, declining 65.2% over three years and 82.5% over five years.